VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ASND
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ASNDAscendis Pharma A/S
$271.19$16.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ASND
  4. Financial Ratios

Ascendis Pharma A/S (ASND) Financial Ratios

Latest Ratios: P/E Ratio 19.0x · EV/EBITDA 64.6x · ROE N/A. (2012–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ASND Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$16.8B$12.9B$8.0B$7.1B$6.8B$7.4B$8.4B$6.5B$2.6B$1.3B$538M
Enterprise Value$17.1B$13.2B$8.3B$7.4B$7.0B$7.1B$7.9B$5.9B$2.3B$1.2B$357M
P/E Ratio →19.01——————————
P/S Ratio12.6618.6821.9226.58133.82947.341214.13483.74243.27880.44116.73
P/B Ratio————26.008.3410.0710.849.197.203.04
P/FCF29.60296.28—————————
P/OCF295.54249.64—————————

P/E links to full P/E history page with 30-year chart

ASND EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—19.0522.7327.90137.20916.961143.29441.76217.00752.7677.58
EV / EBITDA64.65——————————
EV / EBIT———————————
EV / FCF—302.15—————————

ASND Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin85.1%85.1%87.8%83.4%76.3%54.7%100.0%100.0%100.0%100.0%100.0%
Operating Margin-18.9%-18.9%-76.7%-170.8%-1097.9%-5808.6%-4755.1%-1695.1%-1462.6%-7290.3%-1583.2%
Net Profit Margin-31.7%-31.7%-104.0%-180.5%-1139.6%-4931.6%-6025.5%-1630.0%-1229.5%-8097.8%-1487.3%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE———-818.4%-101.7%-44.5%-58.4%-49.7%-55.7%-68.1%-46.1%
ROA-17.7%-17.7%-37.7%-50.3%-53.6%-37.2%-50.6%-43.8%-49.1%-61.8%-42.6%
ROIC-69.1%-69.1%-105.4%-106.5%-77.8%-68.2%-129.9%-899.3%-5304.7%——
ROCE-51.9%-51.9%-154.6%-197.2%-82.8%-47.3%-42.5%-49.9%-66.2%-61.3%-49.1%

ASND Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity————2.350.240.110.06———
Debt / EBITDA———————————
Net Debt / Equity————0.66-0.27-0.59-0.94-0.99-1.04-1.02
Net Debt / EBITDA———————————
Debt / FCF—5.86—————————
Interest Coverage-1.64-1.64-4.70-9.76-17.83-97.17-217.55-177.75-1026.49-1281.21-13745.40

ASND Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.041.041.170.951.298.0314.0212.747.538.6113.67
Quick Ratio0.760.760.840.671.117.2814.0212.747.538.6113.67
Cash Ratio0.580.580.620.541.036.8013.6112.467.148.2213.40
Asset Turnover—0.530.310.320.050.010.010.020.030.010.02
Inventory Turnover0.340.340.150.210.090.05—————
Days Sales Outstanding—83.18166.9049.0984.95103.2420.3221.940.2144.8522.74

ASND Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield5.3%——————————
FCF Yield3.4%0.3%—————————
Buyback Yield0.1%0.1%0.0%0.0%1.5%0.3%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.1%0.1%0.0%0.0%1.5%0.3%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$61M$58M$56M$56M$55M$51M$47M$41M$34M$27M

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Commercial ramp execution dependence

Platform Premium Hidden Behind Trailing Multiples

Based on reported figures, ASND trades at a trailing P/E of 19.28 and forward P/E of 19.02, while EV/EBITDA of 65.55 compresses to 14.41 forward, suggesting earnings expectations are rising sharply as commercial revenue scales.

The gap between trailing EV/EBITDA of 65.55 and forward EV/EBITDA of 14.41 indicates that current EBITDA is depressed relative to what the market expects from the SKYTROFA and YORVIPATH ramp, so the trailing figure likely overstates the true valuation burden. Relative to peers such as INCY at 27.13 EV/EBITDA and ACAD at 22.02, ASND's forward multiple appears moderate, which may reflect investors pricing a platform premium rather than a single-asset discount. Investors should monitor whether forward earnings estimates hold, since a miss would quickly re-rate the stock toward its trailing multiple.

Gross Margin Strength Fails to Reach Operating Line

According to the reported income statement, ASND's gross margin held near 91.2% in 2026Q3 while operating margin reached 33.7% and net margin 20.0%, indicating operating costs still absorb a large share of gross profit.

The spread between a roughly 91% gross margin and a 33.7% operating margin shows that R&D and commercial spending consume most of the gross profit pool, which is consistent with a company still funding a multi-program pipeline. Operating margin has improved sharply from -167.3% in 2024Q3 to 33.7%, suggesting operating leverage is emerging as revenue scales faster than the expense base. The margin trajectory warrants continued monitoring, as the durability of this improvement depends on sustaining revenue growth without a proportional rise in SG&A.

ROIC Recovery Remains Fragile and Uneven

Based on reported quarterly figures, ASND's ROIC moved from -98.3% in 2024Q2 to 9.0% in 2026Q3, but the quarterly series swings between 4.2% and 9.0% in recent periods, so the compounding trend is not yet established.

The recovery in ROIC is largely a function of margin expansion, since asset turnover remains low at 0.15 and capital is tied up in a large, cash-heavy balance sheet that generates little operating return. The ROE of 5.0% in 2026Q3 against 21.9% in 2026Q2 shows how much the headline return depends on one-off items, reinforcing the need to separate recurring earnings from non-operating gains. Investors may want to see ROIC hold above its cost of capital over several consecutive quarters before concluding the business is compounding returns.

Cash Buffer Rebuilt Against Working Capital Swings

As reported in financial statements, ASND's current ratio improved to 2.89 and quick ratio to 2.29 in 2026Q3, up from 1.00 and 0.72 in 2026Q1, reflecting a cash position rebuilt to roughly $980.7M.

The jump in the current ratio from 1.00 to 2.89 across two quarters appears driven largely by cash accumulation rather than inventory build, since the quick ratio tracks the current ratio closely and inventory days are a minor component of working capital. A quick ratio above 2.0 suggests short-term obligations are covered even without inventory liquidation, which is an appropriate buffer for a company with a high fixed-cost base. Under a severe stress scenario, the main risk would be a reversal in working capital timing, which the quarterly cash flow data show can swing by tens of millions in a single period.

Days Payable Flatter Than Headline Liquidity Suggests

Based on reported figures, ASND's cash conversion cycle stood at 676 days in 2026Q3 against 993 days in 2026Q1, a figure driven heavily by a DIO near 922 days that may warrant closer scrutiny of inventory build.

The reported DIO of roughly 900 days is unusually high even for a biologics manufacturer, and combined with DPO near 307 days it produces a CCC that depends on extended supplier terms rather than fast collections. The metric most often misapplied to this business is the headline current ratio, which can flatter a company whose liquidity rests on cash from partner milestones rather than recurring product receivables. Investors should instead examine the cash conversion of operating cash flow to net income and the trend in inventory build relative to revenue before concluding the working capital profile is healthy.

Download Financial Ratios Data

Includes 30+ ratios · 14 years · Updated daily

Consensus & Technical Research Suite
Open ASND Terminal

ASND Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ASND — Frequently Asked Questions

Quick answers to the most common questions about buying ASND stock.

What is Ascendis Pharma A/S's P/E ratio?

Ascendis Pharma A/S's current P/E ratio is 19.0x. This places it at the 50th percentile of its historical range.

What is Ascendis Pharma A/S's EV/EBITDA?

Ascendis Pharma A/S's current EV/EBITDA is 64.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.

Is ASND stock overvalued?

Based on historical data, Ascendis Pharma A/S is trading at a P/E of 19.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Ascendis Pharma A/S's profit margins?

Ascendis Pharma A/S has 85.1% gross margin and -18.9% operating margin.